2026-04-18T00:24:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/4643172025-09-15T18:30:46Zcom_2072_3622col_2072_479130

00925njm 22002777a 4500 dc Carmona-Maurici, Júlia author Rosa, Araceli author Azcona-Granada, Natalia author Peña, Elionora author Ricart-Jané, David author Viñas, Anna author López-Tejero, Maria Dolores author Domingo, Joan C. author Miñarro, Antonio author Baena-Fustegueras, Juan A author Peinado-Onsurbe, Julia author Pardina, Eva author 2023 Severe obesity (SO) can accelerate atherosclerosis and the onset of acute cardiovascular events. The diagnosis of atherosclerosis in the context of a high body mass index (BMI) can be challenging, making the identification of biomarkers clinically relevant. We aimed to assess the usefulness of irisin as a biomarker for subclinical atherosclerosis in participants with SO. This prospective observational study included 61 participants undergoing bariatric surgery for SO, defined as a BMI >40 kg/m2 or >35 kg/m2 with at least one comorbidity. Atherosclerotic plaques were detected by ultrasound. Plasma samples were obtained 1 month before and at 6 and 12 months after bariatric surgery to measure irisin by ELISA. Additionally, subcutaneous samples of adipose tissue were taken and genotyped to identify irisin polymorphism rs3480. Irisin levels were positively correlated with BMI (r = 0.23, p = 0.0064), negatively correlated with atheroma-related parameters (e.g., carotid intima-media thickness), and lower in subjects with atheroma (p < 0.0002). Irisin also showed good overall accuracy for discriminating plaque presence (AUC, 0.81; 95% CI, 0.6956–0.9156). However, the rs3480 polymorphism correlated with neither the irisin levels nor the presence of atheromas. Iirisin could identify subclinical atherosclerosis in SO and might facilitate clinical diagnosis. Irisin Severe obesity Metabolic disorders Subclinical atherosclerosis Bariatric surgery Irisin as a Novel Biomarker of Subclinical Atherosclerosis in Severe Obesity